Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759279 | 0.85 | CYP2C9 (0.51) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL5758934 | 0.85 | CYP2C9 (0.48) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL5757509 | 0.84 | CYP2C9 (0.48) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL27644673 | 0.83 | CYP2C9 (0.47) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL27644675 | 0.83 | CYP2C9 (0.47) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL23608034 | 0.81 | CHRNA7 (0.47) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL4157201 | 0.80 | CYP1A2 (0.52) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL560874 | 0.80 | ELANE (0.57) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL561882 | 0.79 | CYP1A2 (0.51) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL4157069 | 0.79 | CYP1A2 (0.48) | CYP2C9NPSR1CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | CYP2C9 1239/4885NPSR1 1225/4885CYP1A2 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.